XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Overview
USA - NASDAQ:XOMAO - US98419J4040
XOMAO Key Statistics, Chart & Performance
The current stock price of XOMAO is 25.4499 USD. In the past month the price decreased by -0.66%. In the past year, price decreased by -0.52%.
XOMAO Latest News, Press Relases and Analysis
XOMAO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About XOMAO
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ
What does XOMA ROYALTY CORP - XOMA 8 3/8 PERP do?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
What is the stock price of XOMA ROYALTY CORP - XOMA 8 3/8 PERP today?
The current stock price of XOMAO is 25.4499 USD. The price increased by 0.04% in the last trading session.
What is the dividend status of XOMA ROYALTY CORP - XOMA 8 3/8 PERP?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a dividend yield of 8.2%. The yearly dividend amount is currently 0.47.
How is the ChartMill rating for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?
XOMAO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) based on its PE ratio?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
Would investing in XOMA ROYALTY CORP - XOMA 8 3/8 PERP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XOMAO.
When does XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) report earnings?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) will report earnings on 2025-11-06.
XOMAO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to XOMAO. When comparing the yearly performance of all stocks, XOMAO is a bad performer in the overall market: 64.1% of all stocks are doing better.
XOMAO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XOMAO. XOMAO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
XOMAO Financial Highlights
Over the last trailing twelve months XOMAO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -38.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| Debt/Equity | 1.11 |
XOMAO Forecast & Estimates
10 analysts have analysed XOMAO and the average price target is 49.47 USD. This implies a price increase of 94.39% is expected in the next year compared to the current price of 25.4499.
For the next year, analysts expect an EPS growth of 126.86% and a revenue growth 85% for XOMAO